Indiana Healthcare Today
SEE OTHER BRANDS

Get your fresh news on health and wellness in Indiana

Indiana Healthcare Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Indiana Healthcare Today.

Press releases published on September 5, 2025

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, …

DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq

DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq

Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la « Société »), une société …

Publication relating to transparency notifications

Publication relating to transparency notifications

                 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 5, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large …

Publication relative à des notifications de transparence

Publication relative à des notifications de transparence

         INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 5 septembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des …

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock …

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today …

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to …

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to …

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …

Avania renforce son équipe de direction avec la nomination de quatre nouveaux dirigeants

Avania renforce son équipe de direction avec la nomination de quatre nouveaux dirigeants

BILTHOVEN, Pays-Bas et BOSTON, 05 sept. 2025 (GLOBE NEWSWIRE) -- Avania, le leader mondial du conseil et du développement clinique dans le secteur de la MedTech, a le plaisir d’annoncer la nomination stratégique de quatre dirigeants éminents. Alors que le …

Avania verstärkt Führungsteam mit der Ernennung von vier neuen Führungskräften

Avania verstärkt Führungsteam mit der Ernennung von vier neuen Führungskräften

BILTHOVEN, Niederlande und BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avania, der weltweit führende Partner für Medizintechnikberatung und klinische Entwicklung, freut sich, die Ernennung von vier angesehenen Führungskräften in strategische …

메드테크 자문기업인 Avania, 4명의 신규 임원 임명으로 리더십 팀 강화

메드테크 자문기업인 Avania, 4명의 신규 임원 임명으로 리더십 팀 강화

네덜란드 빌트호벤 및 보스턴, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 선도적인 메드테크(MedTech) 자문 서비스와 임상 개발 파트너인 Avania가 4명의 저명한 임원을 전략적 리더십 자리에 임명한다고 발표했다. 메드테크 산업이 점점 복잡해지는 규제 환경과 기술 혁신을 헤쳐 나가는 가운데, 이번에 선임된 신규 임원들은 임상 연구, 규제 업무, 운영, 정보기술, 사업 개발 분야에서 수십 년에 걸친 경험을 결합해 Avania의 …

BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting

BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting

Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem’s proprietary allograft portfolio POMPANO BEACH, Fla., Sept. 05, 2025 (GLOBE …

Streamlined Cancer Tissue Analysis at KFSHRC Improves Patient Journey

Streamlined Cancer Tissue Analysis at KFSHRC Improves Patient Journey

RIYADH, Saudi Arabia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre applies Large-Format Tissue Processing to support a smoother, more reassuring diagnostic experience for patients undergoing cancer surgery. The …

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions